MedGenesis Therapeutix Inc.
MedGenesis Therapeutix (MedGenesis) is a privately-held biopharmaceutical company committed to developing and commercializing highly innovative treatments for patients with serious neurologic disease. MedGenesis' lead program, glial cell-line derived neurotrophic factor (GDNF), is a potentially disease-modifying treatment for Parkinson's disease that has recently completed Phase 2 clinical studies. The program is the first to use MedGenesis' proprietary intermittent convection-enhanced delivery (CED) paradigm for targeted, local drug administration to the affected brain area.
© MedGenesis Therapeutix Inc.
BBC Two will air: "The Parkinsonís Drug Trial: A Miracle Cure?"
28-Feb-2019 (episode 1)
GDNF Phase 2 Primary Study results published in Brain, A Journal of Neurology - "Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinsonís disease"
GDNF Phase 2 Extension Study results published in Journal of Parkinson's Disease - "Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinsonís Disease"
Read the latest news about the GDNF clinical trial on the Parkinson's UK website:
"The results from the trial are not clearcut, but offer promising signs that it may be possible to restore the cells damaged in Parkinson's."